Please login to the form below

Not currently logged in
Email:
Password:

FDA conforms to Plan B ruling

The FDA has announced it will not appeal against a federal court's ruling to allow the morning-after pill, Plan B, to be marketed in the US to girls aged 17 and over

The US Food and Drug Administration (FDA) has announced it will not appeal against a federal court's ruling to allow the morning-after pill, Plan B, to be marketed in the US to girls aged 17 and over.

In March 2009, Judge Edward Korman ruled that the FDA decision had been made on political grounds and was not consistent with the scientific findings made in 2005 by the Centre for Drug Evaluation and Research. 

The FDA has since notified Duramed Research, the manufacturers of the emergency contraceptive, that upon submission and approval of an appropriate application, Plan B can be marketed for use by girls over 17 years old without a prescription.

Duramed Research is a subsidiary of Teva Pharmaceuticals.

23rd April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics